WHO Investment Round: Securing Funding with Transparency Challenges

By João L. Carapinha

November 22, 2024

WHO Investment Round 2023

The World Health Organization’s (WHO) Investment Round 2023 is a significant initiative aimed at mobilizing predictable and flexible resources for WHO’s core work from 2025 to 2028. This initiative seeks to secure $7.1 billion in funding. The aim is to support various global health initiatives and accelerate progress toward health-related Sustainable Development Goals (SDGs). The WHO Investment Round plays a crucial role in addressing pressing health issues, including malaria and cervical cancer, by securing commitments from diverse donors.

Key Objectives and Outcomes of the WHO Investment Round 2023

The primary objective of the WHO Investment Round is to mobilize resources that support initiatives targeting universal health coverage and specific diseases. The goal of raising $7.1 billion is pivotal for the WHO’s plan to address the critical health challenges facing the global community.

Funding Commitments

At the culmination of the Investment Round during the G20 Summit, WHO announced that it had successfully secured financial commitments, covering 53% of its target funding. This amounted to a total of $3.8 billion, which reflects the collective efforts of engaged donors throughout the Investment Round.

Donor Contributions

The commitments involved a diverse array of 70 new contributors, comprising sovereign donors, philanthropic entities, the private sector, and multilateral organizations. Specifically, the contributions are broken down as follows:

– Sovereign donors accounted for $1.02 billion (81% of the disclosed amounts).
– Philanthropies and the private sector contributed $200.5 million (16%).
– Multilateral entities pledged $38 million (3%).

Transparency Concerns

Despite the impressive overall figures, the WHO Investment Round lacks transparency regarding the specific amounts contributed by each donor. This obscurity complicates efforts to discern the distinctions between large and small donors.

– The report indicates that the top ten contributors provided 77% of total pledges, yet it does not detail which countries or organizations these contributors are or the exact amounts they contributed.
– The absence of a detailed breakdown hampers a comprehensive understanding of funding distribution and the relative contributions of various donors.

Broader Engagement

The WHO Investment Round has successfully engaged a broad range of donors which have significantly increased their assessed contributions. This growing enthusiasm for global solidarity enhances international cooperation and financing models.

In summary, the WHO Investment Round has made significant progress in securing funding commitments. However, the ongoing issues regarding transparency limit the analysis of donor contributions. A clearer picture regarding the specific contributions from the various donors is vital to understanding the overall impact of this initiative.

Reference url

Recent Posts

FDA Approval Lumvoa Therapeutics
FDA Approval Lumvoa Therapeutics Redefines Treatment Landscape for Thyroid Eye Disease

By João L. Carapinha

June 29, 2026

The FDA Approval Lumvoa Therapeutics delivers the first full insulin-like growth factor-1 receptor (IGF-1R) antagonist for thyroid eye disease (TED), a rare autoimmune condition that triggers orbital inflammation, proptosis, diplopia, pain, and risk of vision loss.
HIV Treatment Access
Public-Private Partnership Enhances HIV Treatment Access Through Innovative Drug Integration

By João L. Carapinha

June 29, 2026

A new agreement between Merck and the ADAP Crisis Task Force significantly advances HIV Treatment Access by integrating the newly approved single-tablet regimen IDVYNSO™ (doravirine/islatravir) into state AIDS Drug Assistance Programs that served more than 250,000 people with HIV in 2024.
Cemiplimab Cervical Cancer Access
Cemiplimab Cervical Cancer Access Navigating Treatment and Value

By João L. Carapinha

June 24, 2026

Cemiplimab Cervical Cancer Access has been endorsed by NICE for adults with recurrent or metastatic cervical cancer that has progressed after platinum-based chemotherapy, provided patients have not previously received immunotherapy. The final draft guidance confirms that this PD-1 inhibitor deliv...